Skip to content

Feasibility and accuracy of intraoperative molecular PET imaging to improve complete tumor resection

Feasibility and accuracy of intraoperative molecular PET imaging to improve complete tumor resection - MoMas

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00032673
Enrollment
120
Registered
2023-09-13
Start date
2023-10-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Intraoperative specimen PET/CT

Sponsors

Universitätsmedizin Essen
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: General inclusion criteria: Patients with an age = 18 years. Renal cell carcinoma-specific: • Indication for nephron-sparing surgery or nephrectomy. • Indication for resection of a local recurrence • Preoperative staging for renal cell carcinoma according to current guidelines Prostate cancer-specific: • Histologically confirmed adenocarcinoma of the prostate. • Preoperative mpMRI for staging prior to surgery. • At least unfavorable intermediate risk prostate carcinoma: o Category cT2 according to the TNM classification or o ISUP GG3 and o PSA >10 ng/ml • Indication for radical prostatectomy. • Preoperative staging for prostate cancer according to the current guidelines Urothelial carcinoma specific: • Histologically confirmed urothelial carcinoma. • Indication for cystectomy or nephroureterectomy • Preoperative staging of urothelial carcinoma according to the current guidelines.

Exclusion criteria

Exclusion criteria: Patients will be excluded if one or more of the following criteria are met: • Known hypersensitivity to the diagnostic PET agent or its components • Subjects not able to declare meaningful informed consent on their own (e.g. with legal guardian for mental disorders) • Prior administration of another PET tracer of any type in the period of 8 half-lives of the radionuclide • Contraindication for surgery (e.g. polymetastases)

Design outcomes

Primary

MeasureTime frame
Detection rate of positive surgical margins during tumor resection using intraoperative PET/CT with a tumor-dependent tracer (68Ga / 18F / 89Zr – PSMA/FDG/Girentuximab) compared to histopathology.

Secondary

MeasureTime frame
• To compare the diagnostic accuracy of intraoperative specimenPET/CT with conven-tional frozen section examination. • Intraoperative detection rate of positive lymph nodes by intraoperative PET/CT. • Evaluation of radiation exposure of medical staff (surgical team and pathology) • Comparison of tumor burden of whole-body PET/CT with intraoperative PET/CT using machine learning-based image analysis.

Countries

Germany

Contacts

Public ContactChristopher Darr

Universitätsmedizin Essen

christopher.darr@uk-essen.de+49201-72385633

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026